McNicoll, Lewis & Vlak Downgrades Genomic Health to Holld

McNicoll, Lewis & Vlak downgraded Genomic Health (NASDAQ: GHDX) from Buy to Hold in a research report published today. McNicoll, Lewis & Vlak has a $30 price target on the company.

In the report, McNicoll, Lewis & Vlak states, "Genomic Health will launch of a new subsidiary to integrate patient's genetic information into clinical practice to facilitate diagnosis and guide the choice of treatment options, with the first product expected in 2013. Added operating expenses of the subsidiary and uncertainties of product development and market penetration, lead us to lower or recommendation from a BUY to a HOLD."

Shares of Genomic Health closed today at $26.57, down 7.90% from Monday's market close.